Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Mato, A.
24927  Ergebnisse:
Personensuche X
?
1

PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE..:

Barreto, RR ; Patel, K ; Coombs, C...
Hematology, Transfusion and Cell Therapy.  44 (2022)  - p. S139-S140 , 2022
Link: https://doi.org/10.1016/..
 
?
2

P626: FUNCTIONAL SCREENING OF PI3K INHIBITORS STRATIFIES RE..:

Skånland, S. ; Yanping, Y. ; Athanasiadis, P....
HemaSphere.  6 (2022)  - p. 525-526 , 2022
Link: https://doi.org/10.1097/..
 
?
3

PCR123 Patient-Reported Outcomes (PROs) From the informCLL ..:

Sharman, J ; Barrientos, JC ; Ghosh, N...
Value in Health.  25 (2022)  7 - p. S564 , 2022
Link: https://doi.org/10.1016/..
 
?
4

P653: OUTCOMES FOLLOWING TREATMENT WITH A COVALENT BTK AND ..:

Eyre, T. A. ; Hess, L. ; Sugihara, T....
HemaSphere.  6 (2022)  - p. 551-552 , 2022
Link: https://doi.org/10.1097/..
 
?
5

PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE..:

Presenter, RRBN ; Shah, N ; Alencar, A...
Hematology, Transfusion and Cell Therapy.  44 (2022)  - p. S127 , 2022
Link: https://doi.org/10.1016/..
 
?
6

Terson syndrome: A condition to keep in mind:

Cherchi, M. ; Hernández-Hernández, M.A. ; Mato, D.
Medicina Intensiva (English Edition).  46 (2022)  2 - p. 118 , 2022
Link: https://doi.org/10.1016/..
 
?
7

P649: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-2127, A FIRST-IN..:

Mato, A. ; Danilov, A. ; Patel, M. R....
HemaSphere.  6 (2022)  - p. 547-548 , 2022
Link: https://doi.org/10.1097/..
 
?
8

P675: TREATMENT OF HYPERTENSION IN PATIENTS RECEIVING BTK I..:

Shadman, M. ; Voutsinas, J. ; Fakhri, B....
HemaSphere.  6 (2022)  - p. 573-574 , 2022
Link: https://doi.org/10.1097/..
 
?
9

FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERS..:

Hillmen, P. ; Byrd, J. C. ; Ghia, P....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
10

PCN124 REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AND TOTAL..:

Huang, Q. ; Emond, B. ; Lafeuille, M.H....
Value in Health.  23 (2020)  - p. S44-S45 , 2020
Link: https://doi.org/10.1016/..
 
?
11

Measuring quantitative proteomic distance between Spanish b..:

Rodríguez-Vázquez, R. ; Mato, A. ; López-Pedrouso, M....
Food Chemistry.  315 (2020)  - p. 126293 , 2020
Link: https://doi.org/10.1016/..
 
?
12

PCN122 COST-EFFECTIVENESS OF A 24-MONTH FIXED DURATION OF V..:

Huntington, S.F. ; Strunz-McKendry, T. ; Masaquel, A.S....
Value in Health.  22 (2019)  - p. S78-S79 , 2019
Link: https://doi.org/10.1016/..
 
?
13

HYPERTENSION (HTN) IN PATIENTS (PTS) TREATED WITH IBRUTINIB..:

Sarraf Yazdy, M. ; Roeker, L. ; Gashonia, L....
Hematological Oncology.  37 (2019)  S2 - p. 212-213 , 2019
Link: https://doi.org/10.1002/..
 
?
14

UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALL..:

Sharman, J.P. ; Brander, D.M. ; Mato, A....
Hematological Oncology.  35 (2017)  S2 - p. 111-112 , 2017
Link: https://doi.org/10.1002/..
 
?
15

ASMase downregulation protects MAT1A null mice from alcohol..:

Alarcon-Vila, C. ; Baulies, A. ; Ribas, V....
Journal of Hepatology.  66 (2017)  1 - p. S347 , 2017
Link: https://doi.org/10.1016/..
 
1-15